Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Caliber Biotherapeutics LLC Stories

2013-05-22 16:25:27

Anti-CD20-Interferon Alpha Fusion Protein (IGN002) is a promising drug candidate for NHL patients who are resistant to standard therapy WHITE PLAINS, N.Y., May 22, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is committing approximately $6( )million to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber, to co-fund the completion of pre-clinical development, manufacturing, and a Phase I clinical trial for a novel fusion protein that may change...

2013-02-19 08:32:27

NEWARK, Del. and BRYAN, Texas, Feb. 19, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO), and Caliber Biotherapeutics LLC (Caliber) today announced execution of a License and Collaboration Agreement for development and production of recombinant plant-based biopharmaceuticals using iBio's proprietary iBioLaunch(TM) technology and Caliber's unique and proprietary plant-based manufacturing capabilities. (Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO) (Logo:...

2012-11-13 08:35:36

THOUSAND OAKS, Calif. and BRYAN, Texas, November 13, 2012 /PRNewswire-iReach/ -- ImmunGene, Inc. (ImmunGene) and Caliber Biotherapeutics, LLC (Caliber) announced today the launch of Valor Biotherapeutics, LLC (Valor), a joint venture focused on the clinical development and commercialization of monoclonal antibody-interferon (mAb-IFN) fusion protein therapeutics targeting certain cancers. The mAb-IFN fusion protein technology was invented in Professor Sherie Morrison's laboratory at the...